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Flunitrazepam (FNZ) is a sedative benzodiazepine prescribed for the short-term treatment of insomnia. 
However, there are concerns regarding possible carcinogenic or genotoxic effects of this medicine. Thus, 
the aim of this study was to evaluate the cytotoxic, clastogenic and aneugenic effects of FNZ in hepatoma 
cells from Rattus norvegicus (HTC) in vitro and in bone marrow cells of Wistar rats in vivo. These effects 
were examined in vitro following treatment with 0.2, 1.0, 5.0 or 10 μg/mL FNZ using a micronucleus 
test with a cytokinesis block or in vivo using a chromosomal aberration test following treatment with 
7, 15 or 30 μg/mL/kg body weight. The results showed that the benzodiazepine concentrations tested 
were not cytotoxic, aneugenic or clastogenic. However, considering the adverse effects of using this 
benzodiazepine, more studies are required.
Uniterms: Flunitrazepam/cytotoxic effects. Flunitrazepam/clastogenic effects.Flunitrazepam/aneugenic 
effects. Sedative benzodiazepine/adverse effects/in vitro and in vivo study. Chromosomal abnormalities/
medicines effects.
Flunitrazepam (FNZ) é um sedativo benzodiazepínico prescrito para o tratamento da insônia em curto 
prazo. Entretanto, existe a preocupação com relação aos possíveis efeitos carcinogênicos ou genotóxicos 
causados por este fármaco. Então, o objetivo deste estudo foi avaliar os efeitos citotóxicos, clastogênicos 
e aneugênicos do FNZ em células de hepatoma de Rattus norvegicus (HTC) in vitro e em células de 
medula óssea de ratos Wistar in vivo. Foram testadas as concentrações de 0,2, 1,0 e 10 μg/mL de FNZ 
pelo teste do micronúcleo com bloqueio de citocinese in vitro e 7, 15 e 30 μg/mL/kg de peso corpóreo 
para o teste de aberração cromossômica in vivo. Os resultados mostraram que as concentrações do 
benzodiazepínico testadas não foram citotóxicas, aneugênicas ou clastogênicas. Entretanto, considerando 
os efeitos adversos do uso deste benzodiazepínico, mais estudos são necessários.
Unitermos: Flunitrazepam/efeitos citotóxicos. Flunitrazepam/efeitos clastogênicos. Flunitrazepam/
efeitos aneugênicos. Sedativo benzodiazepínico/efeitos adversos/estudo in vitro e in vivo. Anormalidades 
cromossômicas/efeitos de medicamentos.
INTRODUCTION
Flunitrazepam (FNZ) is a potent benzodiazepine 
agonist primarily used as a hypnotic and preanesthetic agent 
across Europe (Woods, Winger, 1997; Druid, Holmgren, 
Ahlner, 2001). FNZ is a sedative benzodiazepine that is 
prescribed for the short-term treatment of insomnia at a 
recommended dose of 0.5-1.0 mg, with a maximum dose 
of 2.0 mg (Ohshima, 2006). FNZ has an appreciable abuse 
potential (Druid, Holmgren, Ahlner, 2001; Ohshima, 
2006) and is among a cluster of “club drugs” misused at 
raves and in other social settings, including in the United 
States, where this drug is not legally available (Woods, 
Winger, 1997; Smith et al., 2002; Britt, Mc-Cange-Katz, 
2005).
Similar to other cerebral modulating drugs, FNZ can 
produce pharmacological effects that include sedation, 
memory impairment, and behavioral disinhibition, which 
is described as an increase in the probability of behaviors 
that typically occur at low frequencies due to social and 
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interpersonal constraints, such as sexual misconduct. 
These disinhibitory and amnesic effects might result in 
increased risky behavior and altered decision-making 
(e.g., violence, other drug use and high-risk sexual 
activity) (Wu, Schlenger, Galvin, 2006; Lane, Cherek, 
Nouvion, 2008).
Individuals who abuse FNZ often commit sexual 
assaults and violent acts (Almeida et al. ,  2010). 
The increasing abuse of both FNZ and ketamine 
hydrochloride has particularly been observed in young 
people in social settings, such as clubs. Frequently, young 
people take FNZ in conjunction with alcohol and exhibit 
euphoria, agitation and amnesia (Druid, Holmgren, 
Ahlner, 2001; Smith et al., 2002). FNZ is becoming 
increasingly abused by young people who use this drug 
in combination with alcohol and then commit violent 
crimes (Almeida et al., 2010).
In addition to these harmful effects, there are 
concerns regarding possible genotoxic or carcinogenic 
effects caused by this medication or its derivatives (Assaf, 
Abdel-Rahman, 1999; Brambilla, Carrozzino, Martelli, 
2007), thereby stressing the importance of cytogenetic 
testing with FNZ.
Short duration test systems are widely used to 
detect environmental mutagens, such as ionizing radiation 
or chemically synthesized substances. These systems 
include cultures of mammalian cells grown in vitro as 
well as cultures of human lymphocytes and cell lines from 
Chinese hamsters and rats (Rattus norvegicus). In turn, in 
vivo test systems, such as rats, respond in a manner similar 
to that observed in vitro. Additionally, a close correlation 
exists between the biological metabolism of rats and that 
of humans, which justifies the use of this animal in the 
identification of substances that may possess mutagenic 
potential in humans (Waters et al., 1996; Natarajan, 2002).
The aim of this study was to evaluate the cytotoxic, 
aneugenic and clastogenic potential of FNZ through 
the induction of micronuclei in cultured hepatoma cells 
in vitro and through the appearance of chromosomal 
aberrations in R. norvegicus bone marrow cells in vivo.
MATERIALS AND METHODS
In vitro
Cell Line – HTC
HTC cells that were derived from a Rattus norvegicus 
hepatoma were provided by Dr. Mário Sérgio Mantovani, 
State University of Londrina – Paraná – Brazil. Cells 
(2x106) were grown in 25 cm2 culture flasks containing 
5 mL DMEM (Gibco), which was supplemented with 
10% fetal bovine serum (Gibco), incubated at 37 °C. 
Accordingly, the lineage cell cycle is approximately 24 
hours.
Treatment Solution
For the negative control, 20 µL of phosphate 
buffered saline (PBS)/mL was added to the culture 
medium (DMEM). The positive control was doxorubicin 
(DXR – Ackros) at a final concentration of 0.2 μg/mL 
DMEM.
Treatments with benzodiazepine FNZ (Rohypnol®) 
(Roche), with the molecular structure shown in Figure 1, 
were performed with four different concentrations of this 
medicine: 0.2 [1], 1.0 [2], 5.0 [3] or 10.0 [4] μg/mL DMEM.
Cytokinesis Block Micronucleus assay (MNCtB)
Cells were incubated for 24 hours with the treatment 
solutions and with cytochalasin B (Sigma, 3.0 μg/mL 
DMEM) to obtain binucleated cells to evaluate their 
cytotoxicity and mutagenicity, as described by Fenech 
(2000). Cells were harvested according to a previously 
published protocol by Oliveira et al. (2002). Briefly, cells 
were trypsinized (500 μL trypsin-0.025% EDTA (Gibco) 
at 37 °C); centrifuged (5 min at 1,000 rpm); hypotonized 
(1.5 mL of 1% sodium citrate) and fixed (5 mL of a 3:1 
mixture of methanol:acetic acid).
All of the experiments were performed in triplicate; 
3,000 binucleated cells were analyzed per treatment to 
assess the frequency of micronuclei (MN) and 1,500 
cells were counted to determine the cytokinesis block 
proliferation index (CBPI). The process for selecting 
binucleated cells, identifying micronuclei and calculating 
the CBPI was followed as described by Fenech (2000). 
The percentage of cytostasis was calculated by the 
following formula (OECD, 2010):
% Cytostasis = 100 - 100 [(CBPITreatment - 1) ÷  
(CBPIControl - 1)].
FIGURE 1 – Fluorine molecule of flunitrazepam. Source: 
www.rsc.org (2013).
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Statistical analysis was performed using an ANOVA 
and Tukey’s test (p < 0.05).
In vivo
Wistar Rats
Six Wistar rats, three males and three females for 
each group, were obtained from the Central Vivarium – 
State University of Maringá (UEM). Experiments were 
performed on 35 days old rats weighing approximately 
100 g body weight (bw). Animals were maintained during 
the period of experimentation in the Central Vivarium 
of the Department of Cell Biology and Genetics/UEM 
under controlled conditions of temperature ± 25 ºC, 
humidity ± 50% and with a photoperiod of 12 hours light/
dark, according to the standards established by the Ethics 
Committee on Experimentation with Laboratory Animals/
UEM (process number: PRO 046/2010).
Treatment Solution
For the negative control, rats were treated with 1 
mL of water/100 g bw (body weight), via gavage, for 
24 hours. The positive control (CO+) was 1.5 mg of 
cyclophosphamide clastogenic drug/1 mL water/100 g 
bw, intraperitoneally administered for 24 hours to assess 
the responsiveness of the lineage.
Treatments  with the benzodiazepine FNZ 
(Rohypnol®) (Roche) were performed by treating rats 
with three concentrations of this medicine: 7 [1], 15 [2] 
or 30 [3] μg/mL of water/kg, via gavage, as calculated by 
an extrapolation of the concentrations used by humans to 
the body weight of rats.
Chromosomal Aberration Test
The chromosomal aberration test was performed 
to obtain bone marrow cells of Wistar rats using the Ford 
and Hamerton method (1956), with some modifications. 
Mitotic cells were interrupted in metaphase with the 
intraperitoneal administration of 0.5 mL/100 g bw of 
colchicine (0.16%) half an hour before euthanasia.
For animal euthanasia, 0.5 mL/100 g bw of 
anesthetic (1 g sodium thiopental/25 mL of distilled water) 
was intraperitoneally administered.
Bone marrow was removed from the femurs with 5 
mL of hypotonic solution (0.075 M potassium chloride). 
The suspension was incubated at 37 °C for 12 minutes, 
centrifuged for 5 minutes and then the supernatant was 
discarded. The material was fixed with 5 mL of methanol 
solution, 3:1 acetic acid and centrifuged for 5 minutes. The 
supernatant was discarded and the fixative was changed at 
least twice. The preparation was performed with a drop of 
suspension on clean slides containing a film of distilled ice 
water. The coloration of the slides was performed using a 
drop from a film of Giemsa solution in phosphate buffer 
(0.12 M Na2HPO4, x 12 H2O and 0.06 M KH2PO4) at a 
ratio of 1:30 at pH 6.8.
The analysis of the slides was performed using a 
light microscope, analyzing 100 metaphases per animal, 
which totaled 600 metaphases for the control and treatment 
groups, and assessing the appearance of alterations, such 
as gaps, breaks, fragments, etc. The results were expressed 
as a percentage of total aberrations.
The cytotoxic evaluation of the mitotic index (MI) 
was calculated from 5,000 cells by sex, totaling 10,000 
cells per group. The MI calculation, as a percentage, was 
performed using the number of dividing cells divided by 
the total number of cells present in the fields.
Statistical calculation was performed using the chi-
square test (a = 0.05).
RESULTS AND DISCUSSION
When examin ing  the  cy to tox ic i ty  o f  the 
benzodiazepine FNZ at various concentrations (0.2, 1.0, 
5.0 and 10.0 µg/mL) in vitro (Table I), the results showed 
that this substance did not affect cytokinesis-block 
proliferation and showed no cytotoxic action in hepatoma 
cells from R. norvegicus. The addition of FNZ did not 
cause the inhibition of cell proliferation but stimulated 
cell proliferation, as shown by the percentage of cytostasis 
(Table I) at all concentrations evaluated: 11.76% at a dose 
of 0.2 µg/mL; 10.29% at a dose of 1.0 µg/mL; 11.76% at 
a dose of 5.0 µg/mL and 14.70% at a dose of 10 µg/mL.
These results differ from those results found by 
Assaf Abdel-Rahman (1999), who showed that a 0.16 mM 
solution of FNZ (50 μg/mL) significantly reduced the 
number of viable rat liver cells after 2 hours of exposure. 
However, although the base concentration used in this 
study was extrapolated to the total weight of the culture 
medium (5 g) based on the highest concentration consumed 
by humans (2 mg) and although concentrations up to 50 
times higher than this concentration were also used, the 
concentrations used in this study are much smaller than 
the 50 μg/mL concentration that was used in Assaf Abdel-
Rahman’s (1999) work, which may explain the lack of 
cytotoxicity observed in the HTC cells.
Non-cytotoxic results were also observed in vivo 
in the bone marrow cells of Wistar rats (Figure 2) treated 
with concentrations of 7, 15 or 30 μg/mL/kg FNZ, 
which suggest that FNZ did not affect the cell division 
index. Moreover, in the case of an acute treatment with 
the extrapolated doses commonly consumed by humans 
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(0.5, 1.0 and 2.0 mg), the absence of toxicity of FNZ is 
noticeable. However, studies that have used high doses 
of FNZ have shown divergent results. One example is 
Namera et al. (2012), who showed that FNZ has acute 
toxic effects in high doses because FNZ caused the death 
of a woman who ingested high doses of FNZ and triazolam 
(another anxiolytic and sedative).
The evaluation of the aneugenic and clastogenic 
potential of FNZ, which was performed by the in vitro 
micronucleus test in HTC cells (Figure 3) and by the in 
vivo chromosomal aberration test in the bone marrow 
cells of Wistar rats (Figure 2), showed that the numbers 
of micronuclei and chromosomal aberrations were not 
statistically different from the negative control at all 
concentrations evaluated. These data suggest that FNZ 
does not possess aneugenic or clastogenic activity. 
Furthermore, the percentage of chromosomal aberrations 
did not differ according to sex, indicating that mutagenic 
activity does not occur in both males and females.
However, in general, one can observe a dose-
dependent effect of FNZ both in vivo and in vitro. As the 
dose increased, the average percentage of chromosomal 
aberrations (7 μg/mL/kg = 0.3%, 15 μg/mL/kg = 0.5% 
and 30 μg/mL/kg = 0.6%) increased in vivo, and the 
average formation of micronuclei (0.2 μg/mL = 19, 1.0 
μg/mL = 20.67, 5.0 μg/mL = 26.33 and 10 μg/mL = 24.67) 
increased in vitro. Staiano et al. (1984) also observed a 
dose-responsive effect for FNZ mutagenicity using the 
Salmonella/microsome mutagenicity test. Peterka et al. 
(1992) also demonstrated that the proportion of living, 
malformed embryos of White Leghorn chickens gradually 
increased when treated with increasing doses of FNZ (0.6, 
6.0 and 20 μg).
In this study, FNZ treatment did not result in 
mutagenicity; these findings are similar to those results 
obtained by Degraeve et al. (1985), who investigated 
the clastogenicity of this medicine by the chromosomal 
aberration test in the bone marrow cells of male mice 
intraperitoneally treated with 850 μg/kg for 12 to 72 hours. 
In addition, other studies have indicated that FNZ was 
not able to reversely mutate the Salmonella typhimurium 
TA100 strain when treated with a concentration of 5,000 
μg/plate and did not cause the formation of mutations in 
the l5178Y gene in mouse lymphoma cells (Brambilla, 
Carrozzino, Martelli, 2007; Brambilla, Martelli, 2009). 
Additionally, FNZ treatment did not damage the single-
stranded DNA of rat liver cells in vivo (Carlo et al., 1989) 
and did not cause chromosomal aberrations in the bone 
marrow cells of mice in vivo (Brambilla, Carrozzino, 
Martelli, 2007; Brambilla, Martelli, 2009).
TABLE I - The mean cytokinesis block proliferation index (CBPI) 
of 1,500 control cells compared with cells that were treated with 
flunitrazepam
Group Total cells analyzed
CBPI 
μ±SD
% Cytostasis
CO- 1,500 1.68±0.09 -
CO+ 1,500 1.84±0.02 23.52
[1] 1,500 1.76±0.09 11.76
[2] 1,500 1.75±0.06 10.29
[3] 1,500 1.76±0.00 11.76
[4] 1,500 1.78±0.09 14.70
CO-: Negative control; CO+: Doxorubicin; FNZ: [1]: 0.2 μg/
mL; [2]: 1.0 μg/mL; [3]: 5.0 μg/mL; [4]: 10 μg/mL.
FIGURE 2 - Percentage of the mitotic index and chromosomal 
aberrations for the negative (CO-) and positive (CO+) control 
groups and for groups treated with concentrations of 7 [1], 15 
[2] or 30 [3] μg/mL/kg of flunitrazepam in vivo. *Statistically 
significant result compared with the negative control (p < 0.001).
FIGURE 3 - The average number of micronuclei (MN) for the 
negative (CO-) and positive (doxorubicin) control groups and 
for groups treated with concentrations of 0.2 [1], 1.0 [2], 5.0 
[3] and 10 [4] μg/mL of flunitrazepam in vitro. * Statistically 
significant result compared with the negative control (p < 0.001).
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Although the results of this study have not shown 
any aneugenic, clastogenic or cytotoxic effects of FNZ, 
subchronic studies with FNZ should be performed to 
evaluate the long-term effects of daily consumption, which 
is typical in humans, and of higher doses to evaluate the 
effects of acute high concentrations, such as in situations 
of abuse.
CONCLUSIONS
The results of this study show that the concentrations 
of the benzodiazepine flunitrazepam tested in vitro 
(0.2, 1.0 and 10 μg/mL) and in vivo (7, 15, and 30 μg/
mL/kg) were not cytotoxic, aneugenic or clastogenic 
by micronucleus test or by the chromosome aberration 
test, respectively. Thus, the extrapolation of daily doses 
consumed by humans showed no potentially harmful 
effects in HTC cells or in the bone marrow cells of Wistar 
rats. However, considering the adverse effects of use of 
this benzodiazepine, further studies should be performed.
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